Lessons for the Administration as It Attempts to Lower Part B Drug Prices
Last month, the Trump administration announced a new strategy for changing how Medicare pays for prescription drugs under Part B, with the aim of lowering drug costs for the program and for beneficiaries. Part of that plan involves contracting with private vendors to purchase Part B drugs from manufacturers at lower prices – an approach tried once before.
On To the Point, Kristi Martin and Jeremy Sharp of Waxman Strategies tell the story of the Competitive Acquisition Program, which Congress established in 2003 — and shelved in 2008 — to test an alternative to physician negotiation of Part B drug prices. What lessons can be learned from that program? And does the administration’s new proposal address the issues that arose in the first attempt?
Medicare part B drug payment model_1x1 Read the post Lessons for the Administration as It Attempts to Lower Part B Drug Prices